Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9338
Title: Renal artery stenosis: a disease worth pursuing.
Austin Authors: Parker, S C;Hannah, A;Brooks, Duncan Mark ;Louis, William J ;O'Callaghan, Christopher J 
Affiliation: Department of Medicine, University of Melbourne, Austin & Repatriation Medical Centre, VIC.
Issue Date: 6-Aug-2001
Publication information: Medical Journal of Australia; 175(3): 149-53
Abstract: Consider renovascular hypertension (HT) when: Newly diagnosed hypertension presents with features that are atypical of essential hypertension; Resistant hypertension is associated with risk factors for atheroma; or Angiotensin-converting enzyme (ACE) inhibitor or angiotensin-II-receptor antagonist therapy is associated with increasing plasma creatinine levels. Atheromatous renovascular HT can often be managed medically, which includes intensive correction of cardiovascular risk factors. ACE inhibitors are probably second-line antihypertensives for patients with unilateral renal artery stenosis and two kidneys. First-line antihypertensives are diuretics, beta-blockers and calcium-channel blockers. Bilateral renal artery stenosis, or a unilateral stenosis in a patient with only one kidney, is an absolute contraindication to ACE inhibition.
Gov't Doc #: 11548082
URI: https://ahro.austin.org.au/austinjspui/handle/1/9338
Journal: Medical Journal of Australia
URL: https://pubmed.ncbi.nlm.nih.gov/11548082
Type: Journal Article
Subjects: Angiography
Angiotensin-Converting Enzyme Inhibitors.adverse effects.contraindications.therapeutic use
Antihypertensive Agents.adverse effects.contraindications.therapeutic use
Combined Modality Therapy
Creatinine.blood
Humans
Hypertension, Renovascular.diagnosis.drug therapy
Kidney Function Tests
Renal Artery Obstruction.diagnosis.drug therapy
Appears in Collections:Journal articles

Show full item record

Page view(s)

22
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.